Retaspimycin

Drug Profile

Retaspimycin

Alternative Names: IPI-504; MEDI-561; Retaspimycin hydrochloride

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Massachusetts General Hospital
  • Class Antineoplastics; Benzoquinones; Macrocyclic lactams; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastrointestinal stromal tumours; Multiple myeloma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 01 Oct 2014 Infinity Pharmaceuticals completes a phase I/II trial in Non-small cell lung cancer with KRAS mutation (combination therapy, second-line therapy) in USA (NCT01427946)
  • 01 Apr 2014 Infinity Pharmaceuticals completes a phase II trial in Non-small cell lung cancer in Taiwan, Russia, Romania, South Korea, Hungary and USA (NCT01362400)
  • 25 Sep 2013 Discontinued - Phase-II for Non-small cell lung cancer in Hungary (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top